CoChat

Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis

Ito, Marcia K., Nanchen, David, Rodondi, Nicolas, Paccaud, Fred, Waeber, Gérard, Vollenweider, Peter, Marques-Vidal, Pedro · 2011 · American Journal Cardiovascular Drugs

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Background Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce coronary heart disease (CHD) rates. However, the cost effectiveness of statin treatment in the primary prevention of CHD has not been fully established.Objective To estimate the costs of CHD prevention using statins in Switzerland according to different guidelines, over a 10-year period.Methods The overall 10-year costs, costs of one CHD death averted, and of 1 year without CHD were computed for the European Society of Cardiology (ESC), the International Atherosclerosis Society (IAS), and the US Adult Treatment Panel III (ATP-III) guidelines. Sensitivity analysis was performed by varying number of CHD events prevented and costs of treatment.Results Using an inflation rate of medical costs of 3%, a single yearly consultation, a single total cholesterol measurement per year, and a generic statin, the overall 10-year costs of the ESC, IAS, and ATP-III strategies were 2.2, 3.4, and 4.1 billion Swiss francs (SwF [SwF1 = $US0.97]). In this scenario, the average cost for 1 year of life gained was SwF352, SwF421, and SwF485 thousand, respectively, and it was always higher in women than in men. In men, the average cost for 1 year of life without CHD was SwF30.7, SwF42.5, and SwF51.9 thousand for the ESC, IAS, and ATP-III strategies, respectively, and decreased with age. Statin drug costs represented between 45% and 68% of the overall preventive cost. Changing the cost of statins, inflation rates, or number of fatal and non-fatal cases of CHD averted showed ESC guidelines to be the most cost effective.Conclusion The cost of CHD prevention using statins depends on the guidelines used. The ESC guidelines appear to yield the lowest costs per year of life gained free of CHD.

Overview

Integrity signals

Registry

Crossref · 10.2165/11586760-000000000-00000

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 4

  1. Szucs, 1998, Eur Heart J, 19, M22
  2. Rickenbach, 1992, Médecine et Hygiène, 50, 350
  3. Martin, 2005, Rev Med Suisse, 1, 531
  4. Tran, 2007, Can J Clin Pharmacol, 14, e205

Cited by

See all 11

Metadata

Authors
Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P.
Affiliations
  • University of Lausanne (CH)
  • Centre Hospitalier Universitaire Vaudois (CH)
Corresponding author
Marques-Vidal, Pedro
Venue
American Journal Cardiovascular Drugs
Published
2011-02
Volume
11
Issue
1
Pages
33-44
ISSN
1175-3277 (ISSN-L)
OpenAlex
W2118330255
Cited by
11
References
49
Citations by year
2016: 3 · 2015: 1 · 2013: 3 · 2012: 1
FWCI
2.29
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
statins, coronary artery disease, primary prevention, cost-effectiveness, economic burden, cardiovascular disease prevention guidelines, ESC guidelines, Adult Treatment Panel III guidelines, Switzerland
MeSH terms
Adult, Aged, Coronary Disease, Cost-Benefit Analysis, Costs and Cost Analysis, Female, Humans, Male, Middle Aged, Health Care Costs, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, General Practice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis. https://app.cochat.ai/papers/10.2165/11586760-000000000-00000
The paper
Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P. (2011). Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis. American Journal Cardiovascular Drugs. https://doi.org/10.2165/11586760-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.